JP2018523676A5 - - Google Patents

Download PDF

Info

Publication number
JP2018523676A5
JP2018523676A5 JP2018508149A JP2018508149A JP2018523676A5 JP 2018523676 A5 JP2018523676 A5 JP 2018523676A5 JP 2018508149 A JP2018508149 A JP 2018508149A JP 2018508149 A JP2018508149 A JP 2018508149A JP 2018523676 A5 JP2018523676 A5 JP 2018523676A5
Authority
JP
Japan
Prior art keywords
histidine
hcl
aniflorumab
polysorbate
trehalose dihydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018508149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018523676A (ja
JP6720293B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/047506 external-priority patent/WO2017031288A1/en
Publication of JP2018523676A publication Critical patent/JP2018523676A/ja
Publication of JP2018523676A5 publication Critical patent/JP2018523676A5/ja
Application granted granted Critical
Publication of JP6720293B2 publication Critical patent/JP6720293B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018508149A 2015-08-19 2016-08-18 安定な抗ｉｆｎａｒ１製剤 Active JP6720293B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562207164P 2015-08-19 2015-08-19
US62/207,164 2015-08-19
PCT/US2016/047506 WO2017031288A1 (en) 2015-08-19 2016-08-18 Stable anti-ifnar1 formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020104494A Division JP7035119B2 (ja) 2015-08-19 2020-06-17 安定な抗ｉｆｎａｒ１製剤

Publications (3)

Publication Number Publication Date
JP2018523676A JP2018523676A (ja) 2018-08-23
JP2018523676A5 true JP2018523676A5 (https=) 2020-04-23
JP6720293B2 JP6720293B2 (ja) 2020-07-08

Family

ID=58052002

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018508149A Active JP6720293B2 (ja) 2015-08-19 2016-08-18 安定な抗ｉｆｎａｒ１製剤
JP2020104494A Active JP7035119B2 (ja) 2015-08-19 2020-06-17 安定な抗ｉｆｎａｒ１製剤
JP2022031581A Pending JP2022066345A (ja) 2015-08-19 2022-03-02 安定な抗ｉｆｎａｒ１製剤
JP2024140769A Pending JP2024161043A (ja) 2015-08-19 2024-08-22 安定な抗ｉｆｎａｒ１製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020104494A Active JP7035119B2 (ja) 2015-08-19 2020-06-17 安定な抗ｉｆｎａｒ１製剤
JP2022031581A Pending JP2022066345A (ja) 2015-08-19 2022-03-02 安定な抗ｉｆｎａｒ１製剤
JP2024140769A Pending JP2024161043A (ja) 2015-08-19 2024-08-22 安定な抗ｉｆｎａｒ１製剤

Country Status (23)

Country Link
US (1) US10125195B2 (https=)
EP (3) EP3337502B1 (https=)
JP (4) JP6720293B2 (https=)
KR (4) KR102669174B1 (https=)
CN (1) CN107921109B (https=)
AU (3) AU2016308262C1 (https=)
CA (1) CA2995222C (https=)
CY (2) CY1123657T1 (https=)
DK (2) DK3337502T3 (https=)
ES (2) ES2818229T3 (https=)
FI (1) FI3769781T3 (https=)
HR (2) HRP20230463T1 (https=)
HU (2) HUE061985T2 (https=)
IL (1) IL257279B2 (https=)
LT (2) LT3337502T (https=)
PL (2) PL3769781T3 (https=)
PT (2) PT3337502T (https=)
RS (2) RS64263B1 (https=)
RU (1) RU2731737C2 (https=)
SG (1) SG10202106970XA (https=)
SI (2) SI3769781T1 (https=)
SM (2) SMT202000483T1 (https=)
WO (1) WO2017031288A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2995222C (en) 2015-08-19 2021-07-13 Medimmune, Llc Stable anti-ifnar1 formulation
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
US20200061015A1 (en) 2018-08-23 2020-02-27 Janssen Biotech, Inc. Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
CN110179746A (zh) * 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
KR102766960B1 (ko) * 2019-11-11 2025-02-11 아스트라제네카 아베 전신성 홍반성 루푸스에서 i형 인터페론 억제
CN115667309A (zh) * 2020-05-29 2023-01-31 阿斯利康(瑞典)有限公司 使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病
IL299215A (en) 2020-06-25 2023-02-01 Medimmune Ltd Prevention of axonal damage through binding of an antibody to amyloid beta 1-42
TW202237647A (zh) 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
AU2021404495A1 (en) * 2020-12-17 2023-07-27 Astrazeneca Ab Anti-il5r antibody formulations
PT4192882T (pt) 2021-04-23 2025-05-02 Astrazeneca Ab Tratamento de nefrite lúpica com anticorpo anifrolumab de recetor inf anti-tipo i
HRP20231255T1 (hr) * 2021-04-23 2024-02-02 Astrazeneca Ab Režim doziranja anti-ifnar1 za potkožnu injekciju
CN117157099A (zh) * 2021-04-23 2023-12-01 阿斯利康(瑞典)有限公司 用于皮下注射的抗ifnar1给药方案
BR112023021868A2 (pt) 2021-04-23 2023-12-19 Astrazeneca Ab Tratamento de lúpus eritematoso cutâneo
US20250002591A1 (en) 2021-05-12 2025-01-02 Astrazeneca Ab Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythermatosus patients
CN113521276B (zh) * 2021-07-13 2022-04-12 江苏荃信生物医药股份有限公司 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂
WO2023284073A1 (zh) * 2021-07-13 2023-01-19 江苏荃信生物医药股份有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法、抗人ifnar1单克隆抗体浓缩溶液的制备方法以及液体制剂
CN113527490B (zh) * 2021-07-13 2022-03-01 江苏荃信生物医药股份有限公司 一种抗人ifnar1单克隆抗体浓缩溶液的制备方法
CA3226744A1 (en) 2021-07-27 2023-02-02 Astrazeneca Ab Treatment of lupus
WO2023057369A2 (en) 2021-10-04 2023-04-13 Astrazeneca Ab Treatment of lupus
EP4422674A4 (en) * 2021-10-29 2025-09-17 Intas Pharmaceuticals Ltd Stable lyophilized formulation of an anti-alpha 4beta7 antibody
WO2023155902A1 (en) * 2022-02-18 2023-08-24 Chongqing Mingdao Haoyue Biotechnology Co., Ltd. Intranasal formulations and anti-sars-cov-2-spike protein antibodies
IN202221038828A (https=) * 2022-07-06 2024-01-12
JP2025533978A (ja) 2022-10-13 2025-10-09 アストラゼネカ・アクチエボラーグ ループスの治療
CN121127499A (zh) 2023-05-19 2025-12-12 阿斯利康(瑞典)有限公司 狼疮的治疗
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202315831D0 (en) 2023-10-16 2023-11-29 Astrazeneca Ab Treatment of skin disease
GB202402824D0 (en) 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6713609B1 (en) * 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
HUE035082T2 (en) * 2004-06-21 2018-05-02 Squibb & Sons Llc Interferon alpha receptor 1 antibodies and their use
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2010512356A (ja) * 2006-12-11 2010-04-22 エフ．ホフマン−ラ ロシュ アーゲー 非経口ａベータ抗体製剤
EP2170268A2 (en) * 2007-06-25 2010-04-07 Amgen, Inc. Compositions of specific binding agents to hepatocyte growth factor
US9308257B2 (en) * 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
HRP20160855T1 (hr) 2008-02-08 2016-09-23 Medimmune, Llc Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda
JP5933975B2 (ja) * 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US20150010634A1 (en) * 2011-10-12 2015-01-08 Ascendis Pharma Ophthamology Division A/S Prevention and treatment of ocular conditions
AU2012328524B2 (en) * 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US20150239970A1 (en) * 2012-10-25 2015-08-27 Medimmune, Llc Stable, Low Viscosity Antibody Formulation
AU2014265624B2 (en) * 2013-05-15 2019-09-12 Medimmune Limited Purification of recombinantly produced polypeptides
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
EP3062814A1 (en) 2013-10-29 2016-09-07 Albumedix A/S Antibody composition
RU2017107847A (ru) 2014-09-03 2018-10-03 Медиммун Лимитед Стабильный состав на основе антитела к il-4r-альфа
JP2018500380A (ja) 2014-12-31 2018-01-11 ノベルメド セラピューティクス，インコーポレーテッド アグリコシル化治療用抗体の製剤
CA2995222C (en) 2015-08-19 2021-07-13 Medimmune, Llc Stable anti-ifnar1 formulation

Similar Documents

Publication Publication Date Title
JP2018523676A5 (https=)
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
EP3316928A4 (en) AUTOMATIC INJECTORS FOR THE ADMINISTRATION OF A MEDICAMENT IN A PREPARED SYRINGE
HRP20211371T1 (hr) Stabilne, vodene formulacije protutijela
EA201792591A1 (ru) Фармацевтические препараты
JP2015057451A5 (https=)
AR107014A1 (es) Formulación farmacéutica acuosa
HRP20221263T1 (hr) Ciklički di-nukleotidni spojevi i postupci uporabe
HRP20200072T1 (hr) Načini doziranja za spojeve klase ehinokandina
JP2015110588A5 (https=)
AR092401A1 (es) Formulaciones de anticuerpos anti-receptor de prolactina (anti-prlr)
JP2019516735A5 (https=)
EA201891606A1 (ru) Композиции и способы для внутривенного введения 2-бром-1-(3,3-динитроазетидин-1-ил)этанона
AR095496A1 (es) Formulaciones de anticuerpos anti-receptor de prolactina
HRP20191137T1 (hr) Formulacije otopina konstruiranih anti-il-23p19 antitijela
MD20150120A2 (ro) Tratamentul bolilor neurodegenerative şi miopatice de agregare proteică prin administrarea parenterală a trehalozei
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
JP2016510326A5 (https=)
PE20170773A1 (es) Formulaciones farmaceuticas, procesos para la preparacion, y metodos de uso
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
EA201892837A1 (ru) Физиологически сбалансированные составы для инъекций, включающие фоснетупитант
JP2016515623A5 (https=)
EA201890788A1 (ru) Препараты оланзапина с замедленным высвобождением
FI3733712T3 (fi) Hoito-ohjelmia ja menetelmiä pesäkekovettumataudin hoitamiseksi ofatumumabia käyttämällä
JP2016534062A5 (https=)